10-Q: Catalyst Pharma Q3 Earnings Soar on FIRDAPSE, AGAMREE Growth

Catalyst Pharmaceuticals reports strong third-quarter and nine-month financial results, driven by robust sales of FIRDAPSE and AGAMREE, despite generic competition impacting FYCOMPA.

Summary

• Total revenues for the three months ended September 30, 2025, increased to $148.4 million from $128.7 million in the prior year period.
• Total revenues for the nine months ended September 30, 2025, rose to $436.4 million from $349.9 million in the prior year period.
• Net income for Q3 2025 was $52.8 million ($0.42 diluted EPS), up from $43.9 million ($0.35 diluted EPS) in Q3 2024.
• Net income for the nine months ended September 30, 2025, was $161.6 million ($1.27 diluted EPS), compared to $108.0 million ($0.87 diluted EPS) in the same period of 2024.
• FIRDAPSE net product revenue increased by 16.2% to $92.2 million in Q3 2025 and by 16.7% to $260.8 million for the nine months ended September 30, 2025.
• AGAMREE net product revenue grew to $32.4 million in Q3 2025 and $81.8 million for the nine months ended September 30, 2025, following its commercial launch in March 2024.
• FYCOMPA net product revenue decreased by 25.8% to $23.8 million in Q3 2025 and by 5.3% to $93.8 million for the nine months ended September 30, 2025, due to generic entry.
• Cash and cash equivalents stood at $689.9 million as of September 30, 2025, with working capital of $723.7 million.
• A new share repurchase program of up to $200 million was authorized, with $8.4 million already repurchased as of November 3, 2025.
• Settlements were reached in FIRDAPSE patent litigation with Teva and Lupin, allowing generic entry no earlier than February 25, 2035, while litigation with Hetero remains ongoing.

Sentiment

Score: 8

Explanation: The company demonstrates strong financial performance with significant revenue and net income growth driven by its key products, FIRDAPSE and AGAMREE. Strategic patent settlements for FIRDAPSE provide long-term clarity, and a new share repurchase program indicates financial strength. While FYCOMPA faces generic competition, this is an expected lifecycle event, and the company is actively pursuing portfolio expansion and AGAMREE development. The overall outlook is positive, with a solid cash position and clear growth drivers.

Positives

• Strong revenue growth with total revenues increasing by $19.7 million (15.3%) in Q3 2025 and $86.5 million (24.7%) for the nine months ended September 30, 2025.
• Significant net income growth, up 20.3% in Q3 2025 and 49.7% for the nine months ended September 30, 2025.
• FIRDAPSE continues to show robust sales growth, increasing by 16.2% in Q3 2025 and 16.7% for the nine months ended September 30, 2025, driven by increased sales volumes.
• AGAMREE's commercial launch in March 2024 has contributed substantially to revenue, with $32.4 million in Q3 2025 and $81.8 million for the nine months ended September 30, 2025.
• The FDA approved an increased maximum daily dose of FIRDAPSE to 100 mg, offering greater treatment flexibility.
• FIRDAPSE has been included in the NCCN Clinical Practice Guidelines for Small Cell Lung Cancer, potentially expanding its market reach.
• Successful patent litigation settlements with Inventia, Teva, and Lupin for FIRDAPSE, securing market exclusivity until at least February 25, 2035, for Teva and Lupin.
• Health Canada approved AGAMREE for DMD in boys four years and older, opening the Canadian market.
• The company maintains a strong cash position with $689.9 million in cash and cash equivalents and $723.7 million in working capital as of September 30, 2025.
• A new share repurchase program of up to $200 million demonstrates confidence in financial health and commitment to shareholder returns.
• Management believes it has sufficient funds to support operations for at least the next 12 months, even without additional capital raises for planned operations.

Negatives

• FYCOMPA net product revenue declined by 25.8% in Q3 2025 and 5.3% for the nine months ended September 30, 2025, due to generic competition following patent expiry.
• Expectations for FYCOMPA net product revenue to continue decreasing in the future as more generic competition enters the market, particularly for the oral suspension version after December 15, 2025.
• Net cash provided by operating activities decreased slightly to $163.8 million for the nine months ended September 30, 2025, from $168.9 million in the prior year period.
• The ongoing FIRDAPSE patent litigation against Hetero, with a trial anticipated for March 2026, introduces uncertainty regarding potential earlier generic entry for FIRDAPSE.
• The investment in Santhera equity securities recognized net losses of $2.1 million in Q3 2025 and $2.4 million for the nine months ended September 30, 2025, primarily due to a decrease in share price.

Risks

• Uncertainty regarding the continued successful commercialization of FIRDAPSE, AGAMREE, and FYCOMPA.
• Risk of not being able to attract and retain qualified personnel necessary to run the business.
• Estimates of the LEMS market size for FIRDAPSE may prove inaccurate, affecting revenue growth.
• Changes in the daily dose of FIRDAPSE taken by patients could impact net product revenues.
• Challenges in locating undiagnosed or misdiagnosed LEMS patients, including those with small cell lung cancer.
• Higher than forecasted patient discontinuation rates for products.
• Difficulty in successfully titrating new FIRDAPSE, AGAMREE, and FYCOMPA patients to stable therapy.
• Inability to demonstrate AGAMREE's advantages compared to other corticosteroids or competitors' products to the FDA and third-party payors.
• DMD patients transitioning to gene therapy treatments may delay or stop AGAMREE therapy.
• Reduced revenue from generic competition for FYCOMPA may require impairment of the intangible asset for FYCOMPA.
• Inaccuracy of any revenue or earnings guidance provided to the public market.
• Payors may not continue to provide coverage and reimbursement for products at current prices.
• Reliance on third-party suppliers and contract manufacturers for sufficient, timely, and quality product supply, and their compliance with cGMP.
• Reliance on third-party distributors to maintain compliance with applicable law.
• Ability to maintain compliance with applicable rules relating to patient assistance programs and contributions to 501(c)(3) organizations.
• Uncertainty regarding the scope of intellectual property and the outcome of challenges to FIRDAPSE and AGAMREE patents.
• Potential for post-closing review by antitrust regulators of previous acquisition transactions or Paragraph IV patent settlements.
• Inability to acquire additional drug products, complete their development, and successfully market them if approved.
• Uncertain outcome of FIRDAPSE patent litigation against Hetero, potentially allowing generic entry before February 25, 2035.
• Patents may not be sufficient to prevent generic competition for FIRDAPSE and AGAMREE after their orphan drug exclusivity expires.
• Impact of adverse changes in reimbursement and coverage policies or regulations from government and private payors, including pricing pressures from the Inflation Reduction Act of 2022, potential MFN pricing, or tariffs.
• Inability to successfully develop additional indications for AGAMREE and obtain commercialization ability.
• Impact on business from a prolonged U.S. government shutdown.
• Uncertainty regarding the scope, rate of progress, and expense of clinical trials and studies, and their success.
• Ability to complete clinical trials and studies on a timely basis and within budget.
• Uncertainty of successful and profitable commercialization of FIRDAPSE and AGAMREE in Canada through KYE, and FIRDAPSE in Japan by DyDo.
• Impact on U.S. FIRDAPSE sales if an amifampridine product is purchased in Canada for use in the United States.
• Unsuccessful efforts to expand FIRDAPSE into other global regions.
• System failures or security/data breaches due to cyber-attacks, directly or through third parties.
• Inability to enhance systems, processes, and procedures to support the growing complexity and scale of the business.
• Tariffs on pharmaceutical imports could adversely affect the business by increasing costs and delaying clinical trials or manufacturing.

Future Outlook

The company expects FIRDAPSE and AGAMREE to continue driving revenue, while FYCOMPA net product revenue is anticipated to decrease further due to ongoing generic competition. It is actively exploring new business development opportunities to expand its rare neurology product portfolio through licensing or acquisitions. The company plans to complete a Phase 1 study for AGAMREE in healthy adults by the end of Q1 2026 and validate a U.S. manufacturing site for AGAMREE by the end of 2026. Management believes it has sufficient funds to support operations for at least the next 12 months, absent large acquisitions, and may raise additional capital for future business development.

Management Comments

• "We believe that this most recent sNDA approval offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS."
• "We believe that steroids are and will continue to remain the foundational therapy for DMD patients and dosed concomitantly with other therapies."
• "AGAMREEs unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid that we hope has the potential to demonstrate comparable efficacy to corticosteroids, with the potential for a better-tolerated side effect profile."
• "This mechanism of action may allow vamorolone to emerge as an effective alternative to the current standard of care corticosteroids in children, adolescents, and adult patients with DMD."
• "We expect to have the results of both parts of this study by the end of the first quarter of 2026."
• "We expect that net product revenue for FYCOMPA will likely continue to decrease in the future, since there is currently generic competition following patent expiry for FYCOMPA tablets."
• "We expect revenues from both the KYE and DyDo agreements to be immaterial in 2025, as distribution ramps up in each jurisdiction and KYE begins to market AGAMREE in Canada."
• "We also believe that we can execute this share repurchase program without impairing the advancement of our business development strategy."

Industry Context

Catalyst Pharmaceuticals operates in the specialized and high-value rare disease biopharmaceutical sector, a segment known for premium pricing and extended market exclusivities. The strong performance of FIRDAPSE and AGAMREE aligns with the industry trend of successful orphan drug commercialization. The decline in FYCOMPA revenue due to generic entry is a typical lifecycle event for patented drugs, underscoring the importance of pipeline diversification and intellectual property protection. The inclusion of FIRDAPSE in NCCN guidelines is a significant validation, potentially broadening its market within the oncology community, reflecting the growing integration of rare disease treatments into broader medical practice. The company's active pursuit of new product acquisitions and development for additional indications for AGAMREE is a common strategy to sustain growth and mitigate risks associated with patent expirations. Broader industry pressures, such as the Inflation Reduction Act and discussions around MFN pricing and tariffs, represent ongoing regulatory and political challenges that could impact future profitability across the pharmaceutical sector.

Legal Proceedings

• Ongoing FIRDAPSE patent litigation against Hetero, challenging all Orange Book-listed patents, with a trial anticipated for March 2026.
• Settlement of FIRDAPSE patent litigation with Inventia on July 30, 2024, where Inventia acknowledged patent validity and infringement, agreeing not to commercialize until February 2037 or earlier entry of another ANDA product.
• Settlement of FIRDAPSE patent litigation with Teva on January 8, 2025, agreeing not to market a generic version earlier than February 25, 2035.
• Settlement of FIRDAPSE patent litigation with Lupin on August 26, 2025, on substantially the same terms as Teva's settlement.
• Settlement of FYCOMPA Paragraph IV litigation in June 2024, with generic entry for both oral suspension and tablet formulations no earlier than December 15, 2025.

Related Party Transactions

• The company holds an investment in Santhera Pharmaceuticals Holding AG, representing approximately 11.26% of Santhera's outstanding ordinary shares, acquired as part of the AGAMREE license agreement. Changes in the fair value of this equity investment are recognized in other income, net.

Stakeholder Impact

• Shareholders: Positive impact from strong financial results, increased EPS, and a new share repurchase program, potentially leading to increased shareholder value. Risk of dilution if future equity offerings occur.
• Patients: Continued access to FIRDAPSE, AGAMREE, and FYCOMPA, with expanded FIRDAPSE dosing flexibility and AGAMREE's potential for better-tolerated side effects. Patient assistance programs aim to ensure affordability.
• Employees: Continued employment and potential for stock-based compensation, with strategic reorganization of field forces for FIRDAPSE and AGAMREE.
• Customers (distributors, specialty pharmacies): Continued supply of products, but changes in payment terms with a major customer could affect cash flow timing.
• Suppliers/Contract Manufacturers: Continued reliance on third parties for manufacturing, with efforts to establish a U.S. manufacturing site for AGAMREE. Potential impact from tariffs on imported pharmaceutical ingredients.
• Regulatory Authorities: Ongoing engagement with FDA for approvals and patent term extensions, and compliance with SEC filing requirements.

Next Steps

• Continue to successfully market and sell FIRDAPSE, AGAMREE, and FYCOMPA.
• Advance the SUMMIT study for AGAMREE to evaluate long-term patient safety and quality of life data.
• Complete the Phase 1 study in healthy adults comparing vamorolone, prednisone, and deflazacort by the end of Q1 2026.
• Validate a U.S. manufacturing site for AGAMREE by the end of 2026.
• Continue to explore near-term accretive, clinically differentiated, and de-risked opportunities for licensing or acquisitions to expand the product portfolio.
• Manage the ongoing FIRDAPSE patent litigation against Hetero, with a trial anticipated for March 2026.
• Execute the new $200 million share repurchase program through December 31, 2026.
• Monitor and adapt to the impact of generic competition on FYCOMPA sales.
• Oversee the lifecycle management and development of AGAMREE through the joint steering committee with Santhera.

Key Dates

Recommendation

Catalyst Pharmaceuticals demonstrates robust financial health and strong growth in its core rare disease products, FIRDAPSE and AGAMREE, which are effectively offsetting the anticipated decline from FYCOMPA due to generic competition. The company's strategic patent settlements for FIRDAPSE provide significant market exclusivity, and the new $200 million share repurchase program signals management's confidence and commitment to shareholder returns. With a substantial cash reserve, active business development, and ongoing clinical programs for AGAMREE, Catalyst is well-positioned for continued growth and value creation in the specialized biopharmaceutical market. The current valuation appears attractive given the strong fundamentals and future prospects.

Keywords

Biopharmaceutical, Rare Disease, Orphan Drug, LEMS, DMD, Epilepsy, FIRDAPSE, AGAMREE, FYCOMPA, SEC Filing, 10-Q, Financial Results, Patent Litigation, Generic Competition, Share Repurchase, Clinical Trials, Drug Development, Commercialization, Biotech